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Abstract 16 
Objectives: A future treatment for uncomplicated malaria will contain at least one 17 
component that exerts a rapid rate of kill (RoK). We describe here the validation and 18 
application of a simple, robust and rapid bioluminescence-based assay for the 19 
determination of the initial RoK in intraerythrocytic asexual stages of Plasmodium 20 
falciparum.  21 
Methods: A modification to the concentration-response bioluminescence (here termed 22 
bioluminescence relative rate of kill, BRRoK) assay, utilizing exposure to fold-IC50 23 
concentrations (0.33x to 9x), is used to monitor the immediate cytocidal effect of 372 open 24 
source compounds for antimalarial drug discovery available through the Medicine for 25 
Malaria Venture’s Malaria Box. 26 
Results: Antimalarial drugs that exert a rapid cytocidal effect produce a concentration 27 
dependent loss of bioluminescence signal that correlates with available in vitro and in vivo 28 
estimates of parasite clearance time and parasite reduction ratio. Following the 29 
measurement of IC50 for the Malaria Box compounds in Dd2
luc
, the BRRoK assay was used to 30 
identify and rank 372 compounds for their initial cytocidal activity. Fifty three compounds in 31 
the Malaria Box show an initial relative RoK greater than that of chloroquine, with 17 of 32 
these with an initial relative RoK greater than that of dihydroartemisinin. 33 
Conclusion: The BRRoK assay provides a rapid assay format for the estimation of a key 34 
pharmacodynamic property of antimalarial drug action. The simplicity and robustness of the 35 
  
assay suggests it would be readily scalable for high throughput screening and a critical 36 
decision-making tool for antimalarial drug development. 37 
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Introduction 41 
The past decade has seen, for the first time in generations, a decline in mortality and 42 
morbidity from malaria, largely on account of the use of effective antimalarials and the 43 
widespread coverage of insecticide-treated bed nets and other transmission preventative 44 
measures.
1
 However, the estimated number of deaths is still very high, estimated at 438,000 45 
in 2015,
2
 the majority of which are among African children under 5 years of age. In the same 46 
period, the malaria parasite has assembled more counter measures than ever before to 47 
overcome chemotherapy with some parts of the world reporting clinical failures to 48 
artemisinin and artemisinin combination therapy (ACTs), the last effective antimalarial drug 49 
class currently available.
3-7
 The need to develop new drugs with novel modes of action, 50 
which circumvent current parasite resistance mechanisms, therefore remains an urgent 51 
priority.
8,9
   52 
Towards this aim, in the past 5 years, the Medicines for Malaria Venture (MMV) has 53 
coordinated the screening of more than 5 million compounds against P. falciparum in vitro.  54 
This has generated nearly 30,000 compounds inhibiting in the submicromolar range.
10-12
  55 
However, there is currently no clear and informed path to rationally triage the 20-30,000 56 
hits that are now at our disposal. At best, the pharmaceutical and academic malaria 57 
research communities will be able to progress 20-30 chemotypes down the traditional 58 
discovery and development pathway within the next decade.  Technology platforms able to 59 
identify the most effective and tractable chemotypes for progression into the drug 60 
development pipeline are therefore urgently needed.  Key features of the sought-after next 61 
generation antimalarial for the treatment of uncomplicated malaria, termed Single Exposure 62 
Radical Cure and Prophylaxis (SERCaP), have been rationalized and have resulted in the 63 
  
recommendation of a series of Target Candidate Profiles (TCPs) for the component parts of 64 
this drug combination therapy. TCP-1 emphasises the requirement for a component part of 65 
SERCaP to rapidly eliminate the initial parasite burden, ideally as fast as artesunate, but with 66 
a minimal essential requirement to do so as fast as chloroquine.
9
  67 
A current bottleneck in antimalarial discovery projects is that the current gold standard in 68 
the determination of killing dynamics for new inhibitors is slow, necessitating between three 69 
to four weeks of recrudescence parasite growth following drug exposure.
13
 To address this 70 
bottleneck, we describe here the validation of a microplate-based bioluminescence assay 71 
that provides, within 6 hours, a determination of a compound’s initial cytocidal action. 72 
Benchmarking these data against existing antimalarial compounds, for which rate of kill 73 
(RoK) pharmacodynamics are known, provides a relative rate of initial kill and thus a means 74 
to triage a compound’s activity against the minimal essential and ideal criteria as TCP1 75 
candidates. The utility of this rapid, simple and robust assay format is demonstrated in a 76 
relative rate of kill screen of the MMV Malaria Box, an open access resource provided for 77 
drug discovery in malaria and neglected tropical diseases.
14
 The MMV Malaria Box contains 78 
400 compounds distilled from the initial large chemical screens performed by St. Jude 79 
Children’s Research Hospital, Novartis and GlaxoSmithKline.
10-12
 These compounds reflect a 80 
cross section of the chemical diversity available in the 20-30,000 hits, providing 200 starting 81 
points for oral drug discovery (termed drug-like) and 200 compounds to explore malaria 82 
parasite biology (termed probe-like). Our findings suggest this bioluminescence relative rate 83 
of kill (BRRoK) assay provides the required throughput and discrimination necessary to assist 84 
in the decision making process to prioritise leads in the 20-30,000 antimalarial compound 85 
set for further development. 86 
    87 
  
Materials and methods 88 
Drug stocks  89 
Antimalarial drugs were sourced from Sigma-Aldrich and prepared as follows: atovaquone 90 
(ATQ, 10mM in dimethyl sulfoxide [DMSO]), artemether (ARM, 50mM in ethanol), 91 
chloroquine (CQ, 100mM in deionised water), dihydroartemisinin (DHA, 50mM in 92 
methanol), mefloquine (MQ, 50mM in DMSO) piperaquine (PPQ, 100mM in ethanol), 93 
pyronaradine (PYN, 100mM in deionised water), quinine (QN, 100mM in ethanol) and 94 
tafenoquine (TFN, 100mM in DMSO) and stored at -20
o
C. The Malaria Box was provided by 95 
the Medicine for Malaria Ventures (www.mmv.org) and was provided as 20 µL solutions of 96 
10 mM concentration in DMSO and stored at -20
o
C. In all experiments, the final maximum 97 
final concentration of solvent was 0.6% v/v. 98 
Plasmodium falciparum cell culture 99 
The transgenic Dd2 P. falciparum clone (Dd2
luc
) expresses luciferase under the control of 100 
Pfpcna flanking sequences to produce a strong peak of temporal reporter expression during 101 
S-phase in trophozoite stage parasites.
15,16
 Dd2
luc
 were cultured using standard continuous 102 
culture conditions (RPMI1640 medium supplemented with 37.5 mM HEPES, 10 mM D-103 
glucose, 2 mM L-glutamine, 100 μM hypoxanthine, 25μg mL
-1
 gentamycin, 4% v/v human 104 
serum, 0.25% v/v Albumax II, 5nM WR99210 and 2.5 μg/mL blasticidin S) at a 2% 105 
haematocrit in an atmosphere of 1% O2, 3% CO2, and 96% N2. WR99210 and blasticidin S 106 
drug selection media were removed 48 h prior to initiation of fluorescence and 107 
bioluminescence assays. Staging and parasitaemia of the in vitro culture were assessed by 108 
light microscopy of Giemsa-stained thin blood smears. Synchronization of cultures was 109 
  
attained using sequential sorbitol lysis treatment,
17
 with experiments carried out at least 110 
one intraerythrocytic cycle later. 111 
Concentration-response assays using bioluminescent and fluorescent assay formats 112 
Trophozoite-stage (20-26 h post-infection) cultures of Dd2
luc
 (100 μL, 2% parasitaemia, 4% 113 
haematocrit, n = 3) were added to 96-multiwell plates containing 100 μL of pre-dosed (a 114 
final five-fold dilution series) complete culture medium. On each assay plate, three wells 115 
containing 200 μL of 2% parasitaemia cell culture (2% haematocrit) in the absence of drugs 116 
served as a positive control (100%), whereas the same culture mix in the presence of a 10 117 
μM concentration of chloroquine served as a negative growth control (0%). The outermost 118 
wells on each plate contained 200 μL of incomplete medium (complete culture medium 119 
without human serum or Albumax II supplements) to minimize edge effects from 120 
evaporation during incubation. 121 
To determine estimates of the IC50
48h
, the parasite inoculum was incubated continuously in 122 
the presence of the compound/drug for 48 h prior to assay. Estimation of the LC50
6h
 was 123 
carried out using a modification of the protocol originally described by Pagiuo et al.
18
 Here 124 
the parasite inoculum was incubated for 6 h in the presence of compound/drug. The 125 
infected erythrocyte cultures were collected by centrifugation (3000g, 5 min at room 126 
temperature) and the medium supernatant discarded. Three repeat washes with 10 127 
volumes of complete cell culture medium and centrifugation were completed before re-128 
suspending the infected erythrocytes in 200 μL of 37°C complete culture medium for an 129 
additional 42 h in the absence of compound/drug prior to assay. Luciferase and Malaria Sybr 130 
Green I fluorescent (MSF) assays were also carried out immediately following the 6 h 131 
  
incubation in drug/compound, this data used to estimate the EC50
6h
. Experiments were 132 
carried out as technical triplicates on the same plate, with three independent biological 133 
repeats of each plate performed.  134 
For bioluminescent assays, relative light units were measured using the luciferase assay 135 
system (Promega, UK). A standard single-step lysis procedure was used throughout.
19
 40 μL 136 
samples of P. falciparum culture were transferred to a white 96-multiwell plate (Greiner, 137 
UK) and 10 μL of passive lysis buffer (Promega, UK) added and homogenized by pipetting. 138 
An equal volume, 50 μL, of the supplied luminogenic substrate was mixed with the lysed 139 
parasites and the bioluminescence was measured for 2 sec in a Glomax Multi Detection 140 
System (Promega, UK).  141 
Fluorescent signals were measured using a standard MSF assay
20
 as modified.
16
 MSF lysis 142 
buffer (100 μL of 20 mM Tris (pH 7.5), 5 mM EDTA, 0.008% (w/v) saponin and 0.08% (v/v) 143 
Triton X-100) containing SYBR green I (1× final concentration, from 5000x stock supplied by 144 
Invitrogen, UK) was added to 100 μL of Dd2
luc
 aliquoted onto a black 96-multiwell plate 145 
(Greiner, UK). Well contents were homogenized by pipetting and incubated for one hour in 146 
the dark at room temperature. The fluorescent signal was measured using the blue 147 
fluorescent module (excitation 490 nm: emission 510–570 nm) in a Glomax Multi Detection 148 
System (Promega, UK). 149 
Irrespective of the assay, growth was expressed as a proportion of the untreated control 150 
(i.e. 100%) and calculated as follows: 100x[μ(S) − μ(−)/μ(+) − μ(−)] where μ(S), μ(+) and μ(−) 151 
represent the means for the sample in question and 100% and 0% controls, respectively. 152 
Note, as a complete kill could not be technically demonstrated to be achieved within 6 h, 153 
  
the 0% control for the LC50
6h
 and EC50
6h
 determination was established as a 48 h continual 154 
exposure to 10µM of chloroquine. The % growth was plotted against log10-transformed drug 155 
concentration and the parameters described above determined using a nonlinear regression 156 
(sigmoidal concentration–response/variable slope equation) in GraphPad Prism v5.0 157 
(GraphPad Software, Inc., San Diego, CA). 158 
 159 
Bioluminescence relative rate of kill (BRRoK) assay 160 
Trophozoite-stage (20-26 h post-infection) cultures of Dd2
luc
 (100 μL, 2% parasitaemia, 4% 161 
haematocrit, n = 3) were added to 96-multiwell plates containing 100 μL of pre-dosed (final 162 
three-fold IC50 dilution series) complete culture medium and mixed by pipetting. The 163 
multiwell plate was incubated for 6 h at 37°C. 40 μL samples from each well were removed 164 
and the bioluminescent signal measured using the luciferase single-step lysis protocol 165 
described above. Controls in each biological replicate consisted of trophozoite stage culture 166 
with no drug added (100%) or uninfected erythrocytes (0%). The mean and standard 167 
deviation (SD) of bioluminescence data from three independent biological repeats was 168 
expressed as a proportion of the untreated control (100%) using the calculation shown 169 
above. For the screening of the MMV Malaria Box (6 h assays using a 9x to 0.3x IC50 series), a 170 
Principle Components Analysis was performed on the bioluminescence endpoints 171 
(expressed as a percentage of untreated control) using the KNIME analytics platform to 172 
reduce the dimensionality of these data set.
21
 As the first principle component captured 173 
89% of the variance in the data, a zero-meaned PC1 value was used to represent the BRRoK 174 
parameter. The Z’ score of the BRRoK assay was calculated as follows: Z′ = 1 − [(3σ(+) + 175 
  
3σ(−))/ μ(+) − μ(−)], where μ(+) and σ(+) are the mean and SD of the no-drug (untreated) positive 176 
control, respectively; μ(−) and σ(−) are the mean and SD from uninfected erythrocytes 177 
(negative control), respectively.
22
 The signal to background ratio was calculated as follows: 178 
[μ(+) − μ(−)]/σ(−). 179 
Results 180 
A microplate-based bioluminescence assay monitors a concentration- and time dependent 181 
loss of parasite viability immediately following drug perturbation 182 
P. falciparum genetically modified to express a luciferase reporter gene (Dd2
luc
) show a time 183 
and concentration-dependent loss of bioluminescence signal immediately, i.e. within 6 h, 184 
following exposure to the rapid acting cytocidal drugs chloroquine (CQ), dihydroartemisinin 185 
(DHA) and artemether (ARM).
16
 By contrast, exposure to the cytostatic drug atovaquone 186 
(ATQ) results in no apparent loss in bioluminescence signal over the same timeframe.
16
 To 187 
validate that this drug-induced loss of bioluminescence reports a loss in parasite viability, 188 
Dd2
luc
 parasites were subjected to a lethality assay adapted from that originally described by 189 
Paguio et al.
18
 Early trophozoite stage parasites were exposed to a serial dilution of 190 
antimalarial drug in a 6 h bolus, the drug was then washed off before replacing the parasites 191 
into culture for 42 h to complete a cycle of intraeythrocytic development. The principle here 192 
is that parasites killed during the drug bolus will not divide after removal of the drug, 193 
whereas those inhibited by the drug will recommence growth upon removal of drug 194 
pressure. A range of antimalarial drug classes were tested to explore the applicability of this 195 
approach, including; the 4-aminoquinoline chloroquine, the 8-aminoquinoline tafenoquine, 196 
the 4-methanolquinolines mefloquine and quinine, the bisquinoline piperaquine, the 197 
  
sesquiterpene lactones dihydroartemisinin and artemether and a napthoquinone 198 
atovaquone.  199 
Three log concentration-response curves, normalised against untreated controls, were fitted 200 
using data derived from either a bioluminescence assay (Luc) or a Malaria Sybr Green I 201 
fluorescence (MSF) assay of DNA content (see Figure S1 for an experimental schema). These 202 
curves (Figure 1 and Figure S2) report the following parameters (Table 1); a 50% effective 203 
concentration recorded immediately following the drug bolus but prior to drug wash-out 204 
(EC50
6h
), a 50% lethal concentration estimate following drug wash out and re-culture (LC50
6h
) 205 
and a 50% inhibitory concentration estimate following 48 h of continuous culture in the 206 
presence of the drug (IC50
48h
).  207 
The majority of drugs show a right-shift in the lethal concentration curve compared to that 208 
of the inhibitory concentration, reflecting the higher concentration of drug required to 209 
affect a kill within a 6 h window of exposure (Figure 1 and Figure S2). As expected, the right 210 
shift was more pronounced for the quinolone drugs than for the artemisinins.
18,23
 The minor 211 
shift in lethal concentration for dihydroartemisinin and artemether likely reflects their 212 
formation of covalent adducts with their target(s), rendering them resistant to the wash 213 
steps, the use of trophozoite stage parasites in this assay as well as their profoundly rapid in 214 
vitro rate of kill.
13,23,24
 As previously shown, IC50
48h
 data developed using either MSF or 215 
bioluminescence assays are essentially identical.
16
 The same observation for the LC50
6h
 assay 216 
data, whilst not unexpected, is shown here for the first time. Clear differences between the 217 
MSF and bioluminescence assay immediately following the 6 h drug bolus (EC50
6h
) are, 218 
however, evident. Here, the intrinsic instability of the luciferase reporter protein (t½ of 219 
approximately 1.5 h)
16
 compared to that of the far more stable DNA biomarker (reported in 220 
  
the MSF assay), offers an apparently more dynamic report of immediate drug action during 221 
this 6 h period. Importantly, the EC50
6h
 values determined using the bioluminescence assay 222 
(without drug wash and reculture) are almost identical to the LC50
6h
 estimated using either 223 
assay format. The observation that the 6 h bioluminescence curve closely fits that of the 224 
lethal concentration curve for the majority of drugs, indicates that the loss of 225 
bioluminescence not only apparently reports loss of viability, but also that this 6 h assay 226 
provides a rapid determination of the immediate cytocidal action of these drugs. The sole 227 
exception, atovaquone, shows no reduction in the bioluminescence signal within 6 h, a 228 
reflection of its previously reported pharmacodynamic killing lag time.
13
 229 
To compare the relative concentration-dependent effects of different antimalarial drugs, a 230 
revised bioluminescence assay was devised that utilised fold-changes in IC50 concentrations 231 
to ensure exposure to equipotent concentrations of drug. Here, Dd2
luc
 parasites were 232 
exposed to a three-fold serial dilution (81 to 0.33xIC50) for 6 h, with the bioluminescent 233 
signal, normalised to an untreated control at the same timepoint, plotted against drug 234 
concentration (Figure 2). These data illustrate an apparent saturation in the immediate 235 
lethal effect of drug concentrations greater than 9xIC50 for all, except atovaquone, of the 236 
drugs tested. This observation is in agreement with the findings of Sanz et al,
13
 who suggest 237 
that at a 10xIC50 concentration the maximal rate of in vitro kill was achieved. Direct 238 
comparison between the data shown in figure 2 indicates an apparent relative ranking order 239 
of artemisinin > chloroquine > 4-methanolquinolines > atovaquone, that is identical to the 240 
relative order of RoK described both in vivo and in vitro for the same drugs.
25-29
 To explore 241 
this correlation further, linear regression analysis was performed between the normalised 242 
bioluminescent signals produced for each drug concentration of drug tested and the in vitro 243 
  
parasite reduction ratio (a Log ratio between parasitaemia at the onset of treatment and 244 
that after 48 h exposure, Log PRR) and parasite clearance time (time of drug exposure to 245 
elicit a 99.9% reduction in parasitaemia, PCT) reported in Sanz et al.
13
 (Figure 3 and Figures 246 
S3 and S4). Comparison of bioluminescence against the PCT shows a strong, and significant, 247 
correlation at higher concentrations of drug, with the slope and intercept of the regression 248 
analysis essentially unchanged at concentrations greater than 9xIC50
 
reflecting an apparent 249 
saturation in the rate of kill achieved at these concentrations (Figure 3c and Figure S3). 250 
Comparisons with the Log PRR show a strengthening trend with higher concentrations of 251 
drug (Figure S4), although these just fail to reach a level of significance (α = 0.05). Here, the 252 
available shared data (artemisinins are excluded as Log PRR only reported as >8) and the 253 
limited distribution in Log PRR for the quinoline drugs used would appear to be the likely 254 
limitations in achieving a significant correlation.  255 
 256 
Screening the Malaria Box for compounds that exert a rapid cytocidal effect 257 
The application of a microplate-based bioluminescence assay to quickly identify compounds 258 
that exert an immediate cytocidal effect was explored using the compound set available in 259 
the MMV Malaria Box. Using a 48 h MSF assay, IC50 data was developed here in the Dd2
luc
 260 
clone for 396 compounds, the remaining 4 omitted as insufficient material was available.  261 
These data have been deposited in the ChEMBL - Neglected Tropical Disease Open Access 262 
repository (CHEMBL3392923). Of these 396 compounds, sufficient material was available for 263 
372 to complete a 6 h bioluminescence cidality assay using a serial three-fold dilution of 264 
compounds between 9 to 0.33xIC50; this range selected to monitor the range of initial 265 
cytocidal action without the saturation effects observed at higher concentrations (Figure 3). 266 
  
We term this the Bioluminescence Relative Rate of Kill assay, as the initial cytocidal activity 267 
of each compound is compared against a set of benchmark antimalarials for which in vitro 268 
rates of action are known. Log concentration-normalised bioluminescence signal plots for all 269 
372 compounds are reported in the online supplementary materials (Figures S5 and S6. See 270 
also Table S1 for compound positions in these figures). Ten assay plates (each with n=3 271 
replicates) of Dd2
luc
 exposed for 6 h to either no drug (100% growth) or uninfected 272 
erythrocytes (0%) allow the Z’ score, signal to background (S/B) ratio and coefficient of 273 
variation (%CV) assay parameters to be determined. The 95% confidence intervals for Z’ 274 
score (0.9-0.97), maximum %CV (0.96-2.98%) and S/B (806-993) indicate a robust and 275 
sensitive microplate-based assay format.
22
 276 
Using the mean and standard deviation of the normalized bioluminescence signal for each 277 
IC50-fold concentration in the BRRoK assay, a Principle Components Analysis was carried out 278 
to capture the concentration-dependent effects in a single parameter (see Figures S7, Tables 279 
S2 and S3 in online supplementary materials). The first Principle Component (PC1) accounts 280 
for 89% of the variance in the 6 h assay dataset with the majority of the loading 281 
contributions provided by the 9x and 3xIC50 data (0.63x[9xIC50] + 0.62x[3xIC50] + 282 
0.41x[1xIC50] + 0.22x[0.33xIC50]). Zero-meaned PC1 values provide a sequential order of the 283 
initial cytocidal effect exerted by the 372 MMV compounds screened (see Table S4 in the 284 
online supplementary materials), with lower value PC1 representing a greater cytocidal 285 
effect. This order of initial cytocidal effect is then informed by comparison against the initial 286 
cytocidal effect provided for each of the benchmark antimalarial compounds, providing the 287 
necessary surrogate information regarding the initial relative rate of kill for the MMV 288 
compounds. As such, the BRRoK assay indicates that 53 MMV compounds exert an initial 
  
rate of kill at least the same as that for chloroquine (PC1=-73.7), with 17 (Figure S8) of these 290 
compounds showing an initial rate of kill at least as good as that of dihydroartemisinin 291 
(PC1=-97.4). Support for the surrogacy of PC1 in informing a compound’s initial RoK is 292 
provided by comparing PC1 with the in vitro estimates of Log PRR and PCT for the 293 
benchmark antimalarial drugs tested (Figure 4).
13
 This comparison shows significant 294 
correlations between both PCT (r
2
=0.91, p=0.003) and Log PRR (r
2
 = 0.78, p=0.05) with the 295 
PC1 values determined in the BRRoK assay. 296 
Plotting PC1 against the IC50 for the MMV compounds screened provides a simple means to 297 
explore the interplay between the IC50 potency and relative initial RoK against a background 298 
of known antimalarial drug benchmarks (Figure 5). Potent, low IC50, compounds with an 299 
initial rapid rate of kill, exemplified by artemisinins (i.e. dihydroartemisinin), occupy the 300 
bottom left quadrant of this plot. Atovaquone, whilst potent in terms of its IC50, is a slow 301 
acting drug and occupies the upper left hand quadrant. This analysis reveals that the 372 302 
Malaria Box compounds tested display a wide range of apparent initial rates of kill, but also 303 
that, as would be expected from previous in vitro assays of rate of kill, that there is no 304 
correlation between IC50 and rate of kill (r
2
=0.1).
13,30
 Also, as would be expected from the 305 
MMV Malaria box, where compounds have been selected on their basis as starting points 306 
for drug discovery programmes rather than IC50 potency, no compound tested falls within 307 
the optimal lower-left quadrant of this plot. 308 
309 
  
Discussion 310 
The development of the next generation of medicines for the treatment of uncomplicated 311 
malaria recognises the need for a combination of small molecule drugs that meets a series 312 
of challenging targets around efficacy, cost and safety.
8,9,31
 Amongst these targets is the 313 
requirement to quickly clear the parasite burden through the action of (at least one) rapidly 314 
acting cytocidal drug within this combination therapy.
9
 Here we describe the development 315 
of a rapid and robust assay for the screening of fast-acting cytocidal compounds against the 316 
intraerythrocytic trophozoite stages of P. falciparum. Moreover, the microplate-based 317 
format and minimal experimental manipulations required to complete the assay offers the 318 
potential for it to be readily scaled for high throughput screening of compound libraries 319 
such as the Tres Cantos Antimalarial Set (TCAMS) to triage hits with this rapid killing kinetic.  320 
The utility of this assay was demonstrated through a medium throughput screen of 372 321 
compounds sourced from the Malaria Box, an open access resource provided by the MMV 322 
to pump-prime antimalarial drug development.
14
 Here the concentration-dependent loss of 323 
bioluminescence signal for these compounds was compared against those for a range of 324 
benchmark antimalarial drugs, providing a simple relative assessment of the initial rate of 325 
kill for each MMV compound. Thus, 53 compounds in the MMV Malaria Box were shown to 326 
have an initial rate of kill at least as good as chloroquine, with 17 of these compounds 327 
showing an initial rate of kill better than that for dihydroartemisinin. This relative 328 
description of the initial rate of kill relates directly to the minimum essential and ideal 329 
criteria, respectively, specified for a TCP 1 component of a future SERCaP drug by MMV.
9
 330 
Thus, whilst BRRoK assay doesn’t provide a direct measurement of the rate of kill in terms of 331 
the currently defined PRR and PCT parameters, it readily meets the challenge of identifying, 332 
  
and discriminating between, fast acting cytocidal drugs – and does so within one working 333 
day. 334 
The development of this assay followed from the observation that the bioluminescent signal 335 
in parasites genetically modified to express a luciferase reporter protein is reduced in a 336 
concentration and time dependent way immediately following drug exposure when exposed 337 
to known cytocidal drugs.
16
 This inherent dynamic response, a result of the short half-life of 338 
the luciferase, provides an apparent indirect report of the viability of the parasite. That is, 339 
dead and dying parasites do not synthesise new luciferase, the remainder being rapidly 340 
turned over. Here, using an adaptation of a lethality assay,
18
 the concentration-dependent 341 
loss of bioluminescence over a 6 h drug bolus was shown to relate with that of the apparent 342 
lethal effect of a range of antimalarial drugs monitored following a drug wash and regrowth 343 
into a subsequent intraerythrocytic cycle of growth.
18
  344 
To facilitate a relative comparison of cytocidal activity between different antimalarial drugs, 345 
the bioluminescence protocol was adapted to use fold-IC50 concentrations of drug bolus. 346 
Comparisons between the loss of bioluminescent signal at 6 h when exposed to between 347 
0.33 to 81xIC50 concentrations correlated significantly with in vitro PCT at 3xIC50 or greater. 348 
Interestingly, the slopes for these correlations remained unchanged at concentrations 349 
greater than 9x IC50, mimicking the observation of Sanz et al., that suggests a 10xIC50 350 
concentration is generally sufficient, irrespective of mode of action of a drug, to achieve its 351 
maximal rate of in vitro kill.
13
 Whilst the losses of bioluminescence signal at 6 h failed to 352 
consistently provide a significant correlation with in vitro PRR, the coefficient of variation 353 
are consistently greater than 0.69 for concentrations of 3xIC50 and more. Given these 354 
observations, the BBRoK assay was adapted to screen the MMV Malaria Box using 355 
  
concentrations between 0.33 to 9xIC50. This choice balancing the apparent saturation in in 356 
vitro cytocidal action at concentrations higher than 9xIC50 and the observation that 357 
concentrations as low as 0.33xIC50 still elicited a measurable loss of bioluminescence from 358 
profoundly rapidly acting drugs such as dihydroartemisinin. A distinction between the 359 
BRRoK and in vitro PRR assays is the use of chloroquine resistant and sensitive strains, 360 
respectively. However, given the approach of using IC50-fold concentrations of drug the 361 
effect on the interpretation of the relative rates of kill was considered minimal, and appears 362 
so from the correlation of benchmark drugs using both assays. The use of the IC50-fold 363 
concentration approach in the analysis of drug-action in chloroquine sensitive and 364 
resistance strains is supported by the observation that the temporal accumulation of 365 
haemozoin shows no difference between these strains when the appropriate 1x or 2x IC50-366 
fold concentration of chloroquine is added.
32
 367 
Potential modes of action have been attributed to 135 compounds in the MMV Malaria Box, 368 
although for most the target association is considered tentative.
33
 Using these data, 369 
compounds exhibiting three modes of action were correlated with the BRRoK assay data to 370 
explore the validity of the assay format (Figure 6). Specifically; inhibition of (i) the bc1 371 
complex of the mitochondrial electron transport chain, (ii) dihydroortate dehydrogenase 372 
(DHODH), a key step in the de novo synthesis of pyrimidines in a parasite that otherwise 373 
lacks a pyrimidine salvage pathway and (iii) PfATP4, a Na
+
-ATPase located in the parasite’s 374 
plasma membrane. These modes of action were selected as in vitro PRR data are available 375 
for drugs/compounds that share these modes of action, with at least ten MMV compounds 376 
annotated for each.
33-38
 Fifteen compounds are annotated as inhibitors of the parasite’s bc1 377 
complex and are all reported in the BRRoK assay as having a slow initial cytocidal action (PC1 378 
  
between 25.2 and 100.9), comparable to the exemplar drug, atovaquone, sharing the same 379 
mode of action (PC1= 55.4, log(PRR)=2.9 and 99.9% PCT=90 hr).
13
 Twelve compounds are 380 
annotated as DHODH inhibitors, with five of these being structural analogues of the 381 
triazolopyrimidine early clinical trial candidate DSM265.
34
 BRRoK data reports these 382 
compounds as sharing a slow initial cytocidal action (PC1 between 23.1 and 68) with this 383 
apparent slow rate of kill correlating with the atovaquone-like in vitro PRR data available for 384 
DSM265 due to a lag-phase of between 24 to 48hr before eliciting its cytocidal activity in 385 
vitro.
34
 Of the 28 potential PfATP4 inhibitors in the MMV Malaria Box,
35
 26 were screened 386 
here. In vitro PRR data are available for the exemplar PfATP4 inhibitors (+)-SJ733,
36
 a 387 
dihydroisoquioline with a slow to moderate (between pyrimethamine and atovaquone) rate 388 
of kill, and KAE609/NITD609,
37
 a spiroindolone with a moderate to fast (between 389 
pyrimethamine and artesunate) rate of kill. The majority of the potential PfATP4 inhibitors 390 
in the MMV Malaria Box were reported in the BRRoK assay (PC1 between -47.4 and -114.9) 391 
as having an initial rate of kill between the moderate mefloquine (PC1=-42.4, log(PRR)=3.7 392 
and 99.9% PCT= 43 hr), comparable to the in vitro PRR reference pyrimethamine 393 
(log(PRR)=3.5 and 99.9% PCT= 55 hr),
13
 and the fast-acting dihydroartemisnin (PC1=-97.4). 394 
The fastest acting PfATP4 inhibitor in the BRRoK assay was the spiroindolone MMV396749. 395 
The Malaria Box also contains five structural analogues of (+)-SJ733.
35
 Of these, four 396 
reported BRRoK data (between -16.4 and 49.1) falling between mefloquine and atovaquone, 397 
supporting the moderate to slow rate of kill of these dihydroisoquinolines. These data, 398 
taken together with the expected relative order of the benchmark antimalarial drugs tested, 399 
validates the application of the BRRoK assay in determining initial cytocidal activity across a 400 
diverse range of chemotypes. 401 
  
Comparison of BRRoK with other available in vitro assays of rate of kill suggests a number of 402 
advantages to our approach. Two alternative assays offer an indirect measurement of 403 
cytocidal activity, either by monitoring mRNA levels or through the use of a modified 
3
H-404 
hypoxanthine incorporation assay.
25,26
 The two remaining alternatives offer a direct 405 
measurement of viability, essentially through the monitoring of erythrocyte re-invasion 406 
(reinvasion into fluorescently labelled erythrocytes) and growth post-drug challenge – i.e.  407 
the current “gold” standard offered through monitoring parasite recrudescence after 408 
limiting dilution.
13,27
  Apart from the recrudescence assay, these formats offer readouts of 409 
parasiticidal activity within 3-10 days, with the recrudescence assay taking between 21-28 410 
days. The advantage of the recrudescence assay, however, is based on the fact that it 411 
provides a direct measurement of rate of kill, albeit in vitro conditions generate PRR values 412 
that are not always directly comparable to in vivo PRR measurements.
13,28,36,39
 The 413 
erythrocyte invasion viability assay, like the BRRoK assay, offers a relative measure of RoK, 414 
with classifications of slow (atovaquone-like), moderate (pyrimethamine-like) and fast 415 
(artemisinin-like).
27
 Comparison of the PC1 values for the 30 MMV compounds and 416 
benchmark antimalarials similarly tested in the erythrocyte-invasion viability assay shows 417 
good correlation (Figure S9), with significant differences between PC1 values for fast and 418 
slow RoK drugs as defined in the invasion assay.
27,30
 Moderate RoK compounds, however,  419 
showed no significance difference to slow and fast RoK compounds when compared to the 420 
BRRoK assay, but the sample size is small and there are outliers in both groups. These 421 
outliers may be potentially interesting as they likely represent differences between 422 
compounds being exposed for 6 h to trophozoites (BRRoK) or for between 24 to 48 h 423 
(invasion assay), encompassing most developmental stages of the intraeythrocytic asexual 424 
cycle, and may provide some guide to lag in cytocidal activity or stage-specific action.  425 
  
The key limitation to the recrudescence assay is that it is only available as a low throughput 426 
tool, due to the technical and time consuming challenge of the assay protocol – but it does 427 
provide the ability to discriminate between whether a compound meets the minimal 428 
essential or ideal TCP1 criteria for RoK. This discrimination between TCP1 candidates is 429 
similarly provided by the BRRoK assay, although here it is provided in 6 h from a microplate 430 
format assay requiring minimal manual intervention beyond a single-step lysis and readout 431 
protocol. The simplicity of this assay format offers a significant opportunity to scale up for 432 
high throughput screening through semi-automation and denser microplate formats. Z’ and 433 
S/B rations comparable to those from the 96-well microplate assay can be achieved using 30 434 
µl of intraerythrocytic culture (2% haematocrit and 2% parasitaemia) indicating that this 435 
robust assay can be readily adapted into a 384- or 1536 - well microplate format. Whilst 436 
offering advantages in terms of speed, simplicity, scalability and discrimination, the BRRoK 437 
assay in its current format defines RoK only in terms of the relative immediate cytocidal 438 
action against trophozoite stage parasites. This assay appears best placed in the early drug 439 
discovery pipeline, with priority hits from BRRoK assay to be subsequently confirmed using 440 
the in vitro PRR assay. 441 
The requirement for transgenic parasites expressing the luciferase reporter gene limits the 442 
genetic backgrounds available for this assay, and does represent a distinct limitation of this 443 
in vitro method when compared to the PRR and erythrocyte invasion assay.
13,27
 However, 444 
these transgenics can be reasonably readily generated using stable episomally maintained 445 
reporter plasmids, with the opportunity to extend the utility of the assay, beyond the 446 
current limitation of trophozoite stage parasites, to explore stage-specific rate of kill 447 
dynamics through the selection of gene flanking sequences that would offer temporal 448 
  
expression at other intraerythrocytic stages. The potential for a revised reporter construct in 449 
developing a cytocidal activity assay in ring stage parasites for the exploration of artemisinin 450 
action and resistance being a particularly relevant target of interest. One disadvantage 451 
evident from this study was that it took significantly longer to generate the IC50 data for the 452 
MMV Malaria Box compounds than to perform the BRRoK assay. Typically, IC50 data from 453 
large high throughput screens are available for the 3D7 strain of P. falciparum, and were 454 
provided with the Malaria Box resource. Given that multiples of IC50 are used in the BRoK 455 
assay, and that the 9xIC50 assay data best correlated with available in vitro PRR and PCT 456 
data, we examined whether Dd2-specific IC50 data was actually needed to triage rapidly 457 
acting cytocidal compounds or whether a similar outcome could be achieved using the more 458 
widely available IC50 data from the 3D7 strain. Using the available 3D7 data to provide for a 459 
9xIC50 concentration against Dd2
luc
, the loss of bioluminescence signal in a single 460 
concentration/single timepoint (6 h) triage assay was carried out with 396 of the MMV 461 
compounds and compared to the same data derived using our Dd2 IC50 values (Figure 7a). 462 
The loss of bioluminescence measured using the 3D7 IC50 concentrations significantly 463 
correlate with those determined using the Dd2 IC50 values (r
2
=0.88 p<0.0001). Looking 464 
specifically at the 53 compounds that the BRRoK assay define as having an initial rate of kill 465 
at least as good as chloroquine, setting a threshold of discovery based on a 50% loss of 466 
bioluminescence signal using the 3D7 IC50 concentration would ensure >95% of these TCP1 467 
candidates would be identified in this simplified assay format using the more readily 468 
available 3D7 data (Figure 7b). The discovery rate using 3D7 IC50 data falls as a more 469 
stringent bioluminescence signal threshold is applied, although the same is similarly true 470 
when using the actual Dd2 IC50 data. This simple triage assay, utilising the opportunities 471 
afforded through denser microplate formats and available 3D7 IC50 data, provides the 472 
  
means for a quick and robust exploitation of the available chemical libraries in our search 473 
for rapid acting cytocidal antimalarial drugs to meet the challenge of malaria control and 474 
eradication in a post-artemisinin era. 475 
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 575 
Figure 1. Monitoring drug-induced loss in parasite viability using a bioluminescence assay. 576 
Panels illustrate log-concentration response curves following exposure to the indicated drug 577 
using either a bioluminescence (LUC) or fluorescence assay (MSF) format. From these 578 
curves, estimates of the IC50
48h
, LC50
6h
 and EC50
6h
 (see main text for definition and key for 579 
symbols used) were determined using each assay format (reported in Table 1). Data 580 
represents the mean of three biological replicates, with SD indicated by error bars. ATQ, 581 
atovaquone; CQ, chloroquine; DHA, dihydroartemisinin; MQ, mefloquine. See Figure S1 for 582 
same charts for artemether, quinine, piperaquine and tafenoquine. Note that non-linear 583 
regression for EC50
6h
 estimates using the MSF assay were not possible. 584 
  
 585 
 586 
 587 
 588 
Figure 2. Equipotent-IC50 concentration-dependent loss of bioluminescence for standard 589 
antimalarial drugs. The mean (error bars represent ±SD from three biological replicates) 590 
bioluminescence signal, normalised against an untreated control, remaining after a 6 h 591 
exposure to the indicated fold-IC50 concentration of drug (see key to right of chart). A serial 592 
three-fold dilution from 81xIC50 to 0.33xIC50 is reported. ATQ, atovaquone; CQ, chloroquine; 593 
DHA, dihydroartemisinin; MQ, mefloquine; PPQ, piperaquine; QN, quinine. 594 
595 
  
 596 
 597 
Figure 3. Correlating the concentration-dependent loss of bioluminescence signal with in 598 
vitro (a) Parasite Clearance Time (PCT, h) and (b) Log Parasite Reduction Ratio (PRR). Each 599 
panel represents on the x-axis the bioluminescence signal, as a % of an untreated control, 600 
following exposure to a 9 x IC50 concentration of drug for 6 h. In vitro PCT and Log PRR data 601 
from the Sanz et al.,
13
 study are plotted on the y-axis. Linear regressions are indicated with a 602 
dotted line, with parameters reported on each chart. Charts representing the effect at 81, 603 
27, 3, 1 and 0.33 x IC50 are shown in Figures S3 and S4. (c) Plot illustrating the apparent 604 
saturation in coefficients of determination (r
2
) derived when correlating in vitro PCT and Log 605 
PRR data against the loss of bioluminescence signal at higher fold-IC50 drug concentrations 606 
tested. ATQ, atovaquone; CQ, chloroquine; DHA, dihydroartemisinin; MQ, mefloquine; PPQ, 607 
piperaquine; PYN, pyronaridine. 608 
609 
  
 610 
 611 
 612 
Figure 4. Correlating the Bioluminescence Relative Rate of Kill (BRRoK, PC1) with in vitro (a) 613 
Parasite Clearance Time (PCT, h) and (b) Log Parasite Reduction Ratio (PRR). Zero-meaned 614 
PC1 data are plotted on the y-axis for antimalarial drugs where in vitro PCT and PRR data are 615 
available from Sanz et al.
13
 Linear regressions are indicated with a dotted line, with 616 
parameters reported on each chart. ATQ, atovaquone; CQ, chloroquine; DHA, 617 
dihydroartemisinin; MQ, mefloquine; PPQ, piperaquine; PYN, pyronaridine. 618 
619 
  
 620 
 621 
Figure 5. Distribution of Bioluminescence Relative Rate of Kill (BRRoK, PC1) against IC50 for 622 
the MMV Malaria Box compounds. Zero-meaned PC1 data for 372 compounds in the MMV 623 
Malaria Box (drug-like in red squares and probe-like in blue circles) and 7 benchmark 624 
antimalarial drugs (black diamonds) are plotted against their IC50 (note: faster initial rates of 625 
cytocidal activity are represented with lower PC1 values). See Table S4 in online 626 
supplementary materials for PC1 and IC50 data for individual compounds. The minimum 627 
essential threshold (dotted line) and ideal threshold (solid line) for TCP1 candidates are 628 
indicated based on the BRRoK assay data for CQ and DHA, respectively. This figure appears 629 
in colour in the online version of JAC and in black and white in the print version of JAC. ATQ, 630 
atovaquone; CQ, chloroquine; DHA, dihydroartemisinin; MQ, mefloquine; PPQ, piperaquine; 631 
PYN, pyronaridine; QN, quinine. 632 
633 
  
 634 
 635 
Print version of this figure 636 
637 
  
 638 
 639 
 640 
Figure 6. Correlating mode of drug action with the BRRoK assay. Zero-meaned PC1 data for 641 
MMV compounds with predicted modes of action that target (i) bc1 complex (blue filled 642 
square), (ii) DHODH (green unfilled square) and (iii) PfATP4 (red filled circles) are plotted 643 
against their IC50.
32
 This figure appears in colour in the online version of JAC and in black and 644 
white in the print version of JAC. ATQ, atovaquone; CQ, chloroquine; DHA, 645 
dihydroartemisinin; MQ, mefloquine; PPQ, piperaquine; PYN, pyronaridine; QN, quinine. 646 
647 
  
 648 
 649 
Print version of this figure 650 
 651 
652 
  
 653 
 654 
Figure 7. Scaling the BRRoK assay – the utility of a single concentration /single time point 655 
assay. (a) Chart illustrating the correlation between the bioluminescence signals (as a % of 656 
untreated control) when Dd2
luc
 is exposed to a 9xIC50 concentration of MMV Malaria Box 657 
compound for 6 h – the x-axis representing data using Dd2 IC50 data derived in this study, 658 
and the y-axis IC50 data from a 3D7 clone (values provided with the Malaria Box resource)
14
. 659 
(b) Plot representing the proportion of the 53 compounds from the full BRRoK assay that 660 
show an initial rate of cytocidal activity at least as good as that of chloroquine (CQ) that 661 
would be identified when the indicated thresholds of bioluminescence signal post-662 
treatment are chosen. The two curves represent the bioluminescence signal thresholds 663 
when 9xIC50 concentrations of either the Dd2 or 3D7 strains are used in this assay. Note that 664 
selection of a 50% bioluminescence threshold, irrespective of the source of the IC50 data 665 
used in the single concentration/single time point assay, identifies >95% of the MMV 666 
compounds shown in this report to have an initial cytocidal activity that would meet the 667 
minimal essential requirement for a TCP1 candidate. 668 
669 
  
 670 
Table 1. IC50
48h
, LC50
6h
 and EC50
6h
 estimates determined using bioluminescence (Luc) and 671 
fluorescence (MSF) assay formats. 672 
 673 
Luc
1
MSF
2
Luc MSF Luc MSF
Chloroquine
3 162 209 1093 1163 1091 nd
4
(150-174)
5 (156-232) (895-1336) (880-1431) (906-1350)
Piperaquine 37.0 42.5 339 376 351 nd
(34.5-39.6) (34.1-52.8) (273-391) (224-547) (232-436)
Mefloquine 10.3 11.4 62.3 74.7 79.8 nd
(8.9-11.9) (8.3-16.6) (51.2-75.8) (59.3-87.5) (52.4-92.1)
Quinine 306 246 1532 2031 1865 nd
(271-346) (205-295) (1142-1953) (1681-3053) (1462-2055)
Tafenoquine 354 373 2356 3207 3169 nd
(285-441) (308-506) (1950-2846) (2215-4365) (2465-3847)
Dihydroartemisinin 3.3 4.1 4.4 6.8 5.6 nd
(3.2-3.5) (3.9-4.8) (3.9-5.0) (5.8-8.7) (4.6-6.2)
Artemether 5.5 10.0 6.7 12.7 7.8 nd
(5.0-6.0) (9.1-10.9) (5.8-7.6) (10.8-14.9) (5.7-10.8)
Atovaquone 2.2 2.6 101 187 nd nd
(1.9-2.6) (1.7-3.7) (73.1-142) (91.9-248)
1
Bioluminescence luciferase assay 
2
Malaria Sybr Green Fluoresence assay 
3
Mean (n≥6 measurements) in nM 
4
not determined 
5
95% Confidence intervals
IC50
48h
LD50
48h
ED50
6h
 674 
